LUCA Science Announces Oral Presentation at the American Society of Hematology (ASH) 2022 Annual Meeting

LUCA Science (LUCA), a pre-clinical stage biotechnology company pioneering a unique modality with intracellular mitochondria organelles as bio-therapeutics, announced the company’s collaborator Professor Takanori Teshima’s group at the Department of Hematology of Hokkaido University will give an oral presentation at the ASH 2022 Annual Meeting held in New Orleans, Louisiana, the United States between December 10-13, 2022.

The presentation will demonstrate the enhanced effect of Anti-CD19 CAR-T cells treated with LUCA’s proprietary structurally and functionally intact mitochondria (Q) produced with novel mitochondrial isolation technology. Transfer of “Q” improved in-vitro and in-vivo anti-tumor activities of CAR-T cells in association with improved metabolic fitness (Fig. 1), proliferation, and cytokine production, and suppression of exhaustion of CAR-T cells. Q-treated CAR-T cells also led to significantly reduced tumor volume (Fig. 2) and improved survival in B-cell lymphoma mice compared with control and regular CAR-T group. Transfer of “Q” could be a useful adjunctive method in combination with various other genetical and pharmacological approaches to enhance the effectiveness of CAR-T cell therapy and potentially address challenges with T-Cell exhaustion and senescence in the future.

The abstract is now available at:

https://ash.confex.com/ash/2022/webprogram/Paper162535.html

Title: Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells

Presenter: Shinpei Harada, Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo City, Japan

Session Name: 703. Cellular Immunotherapies: Basic and Translational III

Session Date: Monday, December 12, 2022

Presentation Time: 16:45 (EST)

Abstract Number: 974

Location: Ernest N. Morial Convention Center, La Nouvelle Orleans Ballroom C